Key Highlights

  • ImmuPharma plc (LSE:IMM) continues to target a value-enhancing commercial deal for its P140 autoimmune platform in 2026.
  • First-half 2026 results showed an operating loss of £1.1 million, slightly improved from £1.2 million, though the overall loss rose to £4.7 million due to a derivative revaluation.
  • The company raised £6.47 million in equity funding during 2026 to support Kapiglucagon development and P140 partnering.
  • With less than three months of 2026 remaining, investors are watching closely for news of a P140 licensing agreement.

Why Is ImmuPharma (LSE:IMM) in Focus Today?

On 12 October 2026, ImmuPharma plc (LSE:IMM) is in focus as the final quarter of the year puts a spotlight on its stated goal of securing a P140 deal in 2026. The company has repeatedly said that partnering discussions are advancing and that P140 remains a core value driver. As the year end approaches, the market is increasingly sensitive to any update on timing.

Investor forums and social media have been active with debate about whether a deal can be signed before the end of December. The company's history of extended timelines means that expectations are mixed, adding to volatility.

What Does ImmuPharma Do?

ImmuPharma is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. It is based in London, with research facilities in France and Switzerland, and is listed on AIM. The company is led by Tim McCarthy, who serves as Chairman and Chief Executive Officer.

Its two key assets are P140, an autoimmune technology platform, and Kapiglucagon, a treatment being developed for type 1 diabetes. ImmuPharma also has an interest in Incanthera plc.

P140: The Core Value Driver

P140 is ImmuPharma's lead programme in autoimmune diseases. Significant progress has been made in recent years, culminating in a new patent application filed in August 2025 covering a novel diagnostic test and precision treatment approach. In March 2026, the company provided a positive update on the intellectual property position after receiving the first Combined Search and Examination Report on the UK patent application.

In June 2026, the company noted early-stage research published by the University of Murcia in the journal Autophagy relating to P140 and its potential use in glioblastoma, an aggressive brain cancer. Potential partners that have shown interest in P140 include several of the world's top ten pharmaceutical companies.

Half-Year Results and Funding

For the six months to 30 June 2026, ImmuPharma reported an operating loss of £1.1 million, compared with £1.2 million a year earlier. The overall loss rose to £4.7 million from £1.9 million, mainly because of a £3.36 million finance loss on the revaluation of a derivative financial asset linked to its funding arrangements. Cash at 30 June 2026 stood at £0.7 million, up from £0.4 million a year earlier.

In March 2026, the company announced a £6 million subscription at 6.0 pence per share, plus a retail offer of up to £1.5 million. In total, ImmuPharma raised £6.47 million in equity funding, which supports accelerated development of Kapiglucagon while keeping P140 partnering a priority.

Why P140 Matters to Big Pharma

Autoimmune diseases, such as lupus, are a large and growing area of medical need, and many patients still rely on treatments that broadly suppress the immune system and can cause significant side effects. P140 is designed to work in a more targeted way. The new patent application covering a diagnostic test alongside a precision treatment approach is intended to support the commercial case by helping identify patients most likely to respond. That combination is attractive to large pharmaceutical companies seeking differentiated assets. A licensing deal would typically include an upfront payment, development milestones and royalties, which could transform the finances of a company of ImmuPharma's size.

Risks Investors Are Weighing

The biggest risk is that a P140 deal is delayed again or signed on terms below market hopes. The company has already pushed back its target once, from the end of 2025 to 2026. Drug development carries high scientific and regulatory risk. Funding arrangements linked to the share price can increase volatility in reported results. Further fundraising could dilute shareholders if a deal does not arrive.

What Are Investors Watching Next on LSE:IMM?

The key catalyst is a signed P140 licensing or partnership agreement. Investors are also watching for progress on Kapiglucagon, updates on the UK patent application, any further research publications and the company's cash runway into 2027.

Outlook for ImmuPharma

ImmuPharma (LSE:IMM) is approaching a decisive period. A P140 deal before year end would validate years of work and could reshape the company's finances, while further delays would test investor patience.